While CNSA’s Clinical Proceedings undertake an examination of various unmet needs in neurology, Clinical Awareness Initiatives focus on other important topics within the practice of health care and the policy and regulatory environment that shapes that care.

The FDA's Accelerated Approval Program

With a number of drugs for a range of neurological conditions being considered via the FDA’s Accelerated Approval process, there’s no better time than now to undertake a Clinical Awareness Initiative about the pathway 


CNSA is planning for a two-phase initiative that will begin with an assessment of neurologists’ perceptions and gaps in understanding about Accelerated Approval through a nationwide survey of neurologists and nurse practitioners who work in neurology. The results will be compiled into a summary report that will feature key survey findings and demographic information about survey participants 

White Paper and Companion Resources

The insights gleaned from the survey will then be used to develop materials, beginning with a white paper, to help increase awareness about the Accelerated Approval pathway, overcome gaps in awareness and correct misperceptions. 

CNSA will also host an educational webinar and produce social graphics. These resources will be shared via CNSA’s regular programming and upcoming in-person meetings, as well as through social and digital media and via coalition partners. 


CNSA’s webinar “FDA’s Accelerated Approval Program: Facts, Myths & the Perspectives of Neurologists & Neurology Care Providers” happened on March 1. Watch the 45-minute program below.

Timeline and Support

This initiative began in September 2022 and is schedule to run through February 2023.  

The Accelerated Approval Clinical Awareness Initiative is being supported in part with contributions from Biogen, Lilly and PhRMA.